SlideShare a Scribd company logo
Antidepressants II
Brian J. Piper, Ph.D., M.S.




               January 28, 2013
Goals
• Light therapy for Seasonal Affective Disorder
• Tricyclics & Tetracyclics
• Monoamine Oxidase Inhibitors
• Serotonin Norepinephrine Reuptake Inhibitors
  (SNRI)
• Saint John’s wort
• STAR*D
Seasonal Affective Disorder

 • Depressive symptoms in fall-winter
 • Light-Therapy (10k lux, 30 min/day)
     – retina -> hypothalamus (2) -> pineal (3)
     – morning/ evening
     – rapid therapeutic onset (days)
     – good safety profile

                                                       2   3



Pail et al. (2011). Neuropsychobiology, 54, 162-164.
Light-Therapy Meta-Analysis
 • Effect Size = (mean            Experimental   – meanControl)/ Standard Deviation)

      – 0.20: small
      – 0.50: medium
      – 0.80: large
                                                                                       <- 0.84




Golden et al. (1995). American Journal of Psychiatry, 162(4), 656-662.
Tricyclic Antidepressants (TCA)
•   Developed from antipsychotic drugs (1960s)
•   MOA: NET/SERT inhibition; anticholinergic
•   Gold standard for efficacy
•   Side effects: sedation
•   Concern with overdose
Affinity (dirty drugs)
                     --------------------------------------------------------------------------- ----------------


   ->




Eur J Pharmacol. 340 (2–3): 249–258; Psychopharmacology, 114 (4): 559–565.
Tetracyclic Antidepressant (TeCA)
     •   Example: mirtazapine (Remeron)
     •   MOA: α2 & 5-HT2 antagonist
     •   Efficacy: equivalent to TCA
     •   Adverse Effects: weight gain, somnolence
     •   Other: onset faster than SSRIs




Watanabe et al. (2011). Cochrane Review, Issue 11, CD006528
http://www.howjsay.com/index.php?word=mirtazapine&submit=Submit
Serotonin & Norepinephrine Reuptake
             Inhibitors
•   Example: venlafaxine (Efexor)
•   MOA: SERT/NET
•   Efficacy: good ( > SSRIs)
•   Adverse Effects: nausea, somnolence, sexual
•   Half-life: 5 hours
SSRI Discontinuation Syndrome

   • Occurs for ≈2 weeks following withdrawal of
     antidepressants that block SERT
   • Symptoms
        – Flu-like: nausea, dizziness, diarrhea
        – “brain zaps”
        – emotional volatility
   • Solution: prolonged tapering

Example Patient (0:52 – 1:13, 4:45 – 6:30): http://www.youtube.com/watch?v=x0HUtRCEMyk
Long but sensitive (10 min): http://www.youtube.com/watch?v=2Bt2ftSgDDQ
Nielson et al. (2011). Addiction, 107, 900-908.
Monoamine Oxidase
  • MAOA : 5-HT, NE, DA, tyramine
  • MAOB : phenyltheylamine, DA, tyramine
  • Inhibition:
     – Old (1950s): irreversible/non-selective
     – New (1990s): reversible/selective (MAOA)




Stahl, S. (1998). Essential Psychopharmacology, p. 580.
Monoamine Oxidase Inhibitors
•   History: tuberculosis (serendipity)
•   Example: phenelzine (Nardil)
•   MOA: blocks breakdown of NE, 5-HT > DA
•   Efficacy: excellent
•   Adverse Effects: postural hypotension
MAO-I & “cheese” effect
      • Old view: avoid cheeses, alcohol, etc.
      • New View: avoid aged cheese, spoiled meats,
           – Typical American diet does not contain clinically
             meaningful levels of tyramine (10 mg)




Stahl, S. (2008). Essential Psychopharmacology, p. 587-589.
MAO-I & “cheese” effect
    • New View: avoid aged cheese (Cheshire,
      Danish bleu)




McCabe-Sellers et al. (2006). J of Food Composition & Analysis, 19, S58-S65.
Serotonin Syndrome
   • Cluster of autonomic, motor & mental status
     changes resulting from excess 5-HT (5-HT2A)
                                                                Agents
                                                                MAO-Is
                                                                TCA
                                                                SSRIs
                                                                opiate analgesics
                                                                cough medicines (OTC)
                                                                antibiotics
                                                                triptans
                                                                anti-nausea
                                                                herbal products
                                                                abused drugs




Boyer & Shannon (2005). New England Journal of Medicine, 352, 1112-1120.
Case of Libby Zion
• ER visit for fever, agitation, shaking
  movements                                1965 - 1984

• Interns administered meperidine, later
  restraints
• Hyperthermia & cardiac arrest
• Intern hours/week = 70
Bupropion
     • MOA: ?, NET & DAT inhibitor
     • Adverse Effects: dry mouth, high dose seizures
     • Efficacy:
          – monotherapy ≈ SRI
          – augmentation: better than monotherapy
     • Other: APA recommends as a first-line therapy
       for moderate depression



Moreira, R. (2011). Clinical Drug Investigation, 31(S1), 5-17.
Prior              Sequenced Treatments
             Antidepressant     Alternatives to Relieve
                                Depression (STAR*D)
             Trials
Multi-site   Yes                Yes

Blinded      Yes- Randomized    No-Open
             Controlled Trial
Comorbid excluded               included
Condition
Patients
Duration 6-12 weeks             years
STAR*D Design & Results




    25.5%   26.6%   25.5%   39.0%   32.9%   29.4%   41.9%




Remission: Level 1: 32.9%; Level 2: 30.6%, Level 3: 13.6%
            Level 2: Switch = 27.0%; Augment = 35%
Questions
• If you had a family member with MDD, based
  on the STAR*D results, consider:
  – How good (efficacious) is the gold standard?
  – Is there an advantage of augmentation versus
    switching?
  – Were any other findings unexpected?
MDD: Endocrine Component?




Stahl (2008). Essential Psychopharmacology, p. 616-616.
SRIs & Pregnancy
• Pregnancy is a high-risk period for depression
• SRIs may carry slight risks for the fetus
  – persistent pulmonary hypertension
  – low birth weight
• Untreated MDD does cause fetal risk
Summary
               • Best ----------------------------------Worst

Tolerability           SRI > SNRI     > TCA    >     MAO-I
Efficacy               TCA > MAO-I    > SNRI       > SRI
-----------


Stahl (2008). Essential Psychopharmaology, p. 519.   -----------------
Saint John’s wort
           (Hypericum perforatum)
•   MOA: ?, SERT
•   Adverse Effects: photosensitivity
•   Concern: quality control
•   Efficacy: mild to moderate depression
MDD Trial
                        -----------------------------------------------------------------------------




                                                                                                        Quit
                                                                                                        27%-29%




Davidson et al. (2002). Journal of the American Medical Association, 287, 1807-1814.
Saint John’s wort
   •   MOA: ?, SERT
   •   Adverse Effects: photosensitivity
   •   Other: ↑CYP3A4
   •   Efficacy: “The available evidence suggests that the
       hypericum extracts tested in the included trials:
       a) are superior to placebo in patients with major
            depression;
       b) are similarly effective as standard antidepressants;
       c) and have fewer side effects than standard
            antidepressants.”


Linde et al. (2009). Cochrane Reviews, DOI: 10.1002/14651858.CD000448.pub3
Self-Test
• The only antidepressant whose mechanism of
  action includes inhibiting NET & DAT is:
  – A) hypericum perforatum
  – B) fluvoxamine
  – C) mirtazapine
  – D) bupropion
  – E) clomipramine

More Related Content

PPTX
Antidepressants Part I
PPTX
Depression
PPTX
Pharmacotherapy of depression
PPTX
Antidepressants
PPTX
Systemic Pharmacology Of Autonomic Nervous System. Sympathomimetics Agents
PPTX
Antidepressants
Antidepressants Part I
Depression
Pharmacotherapy of depression
Antidepressants
Systemic Pharmacology Of Autonomic Nervous System. Sympathomimetics Agents
Antidepressants

What's hot (20)

PPT
Antihistaminics divya
PPT
Ssri n snri
PPTX
Antipsychotics agents
PDF
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
PDF
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
PPTX
CNS stimulants & cognitive enhancers
PPTX
Antipsychotics and updates
DOCX
Psychosis pharmacology
PPTX
Sympathomimetics
PPT
New anti epileptic drugs
PPTX
Antipsychotic drug
PPTX
Antidepressants
PPTX
Pharmacotherapy of antipsychotics
PPTX
Parkinsonism treatment
PPTX
Antipsychotic agents
PPTX
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
PPT
SSRI poisoning
PDF
Antipsychotics - Pharmacology
PPTX
Adrenergic drugs 2017
PPT
Sedative hypnotics.ppt - dr dhriti
Antihistaminics divya
Ssri n snri
Antipsychotics agents
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Classification of Antidepressants & “Diagnosis & Pathophysiology of Depression”
CNS stimulants & cognitive enhancers
Antipsychotics and updates
Psychosis pharmacology
Sympathomimetics
New anti epileptic drugs
Antipsychotic drug
Antidepressants
Pharmacotherapy of antipsychotics
Parkinsonism treatment
Antipsychotic agents
Vortioxetine Brintellix Trintellix Clinical and Pre-clinical Data
SSRI poisoning
Antipsychotics - Pharmacology
Adrenergic drugs 2017
Sedative hypnotics.ppt - dr dhriti
Ad

Viewers also liked (6)

PPT
Anti depressant and its classifications
PPT
Antidepressants Tca Ssri
PPTX
Antidepressents Med Chem Lecture
PPTX
Serotonin receptors agonists & antagonists
PPTX
Serotonin agonist &antagonist
Anti depressant and its classifications
Antidepressants Tca Ssri
Antidepressents Med Chem Lecture
Serotonin receptors agonists & antagonists
Serotonin agonist &antagonist
Ad

Similar to Antidepressants Part II (20)

PPTX
Psychopharmacology of Anxiety: Part II OCD & PTSD
PPTX
Treatment approach to resistant depression
PPTX
Drug therapy of depression
PPTX
Antipsychotics Part II
PPTX
Current and future research developments in mood disorders psychopharmacology
PPTX
The Integrative Treatment of Depression, Schizophrenia & Autism - IMMH 2015
PPTX
anti depressants.pptxxxxxxxxxxxxxxxxxxxxxxxxx
PPTX
Neuropharmacology: Affective Disorders
PPT
05 antidepressants by ravikiran
PPTX
Agents for Brain Injury
PPT
Power point presentantation on antidepressants
PPT
Dra. Naomi A. Fineberg - Simposio Internacional ' La enfermedad de la duda: e...
PPTX
Assessing the Appropriateness of Oral Ketamine in Depression
PPTX
PPTX
New Antidepressant Dr.Rahul.pptx
PPTX
Antidepressants BY Dise.pptx
PDF
Antidepressants. CNS stimulants.pdf
PPT
Antidepressant pharmacology
PPTX
Management of anxiety spectrum disorders
PPT
Antidepressants. Mood Stabilizers. Psychostimulants
Psychopharmacology of Anxiety: Part II OCD & PTSD
Treatment approach to resistant depression
Drug therapy of depression
Antipsychotics Part II
Current and future research developments in mood disorders psychopharmacology
The Integrative Treatment of Depression, Schizophrenia & Autism - IMMH 2015
anti depressants.pptxxxxxxxxxxxxxxxxxxxxxxxxx
Neuropharmacology: Affective Disorders
05 antidepressants by ravikiran
Agents for Brain Injury
Power point presentantation on antidepressants
Dra. Naomi A. Fineberg - Simposio Internacional ' La enfermedad de la duda: e...
Assessing the Appropriateness of Oral Ketamine in Depression
New Antidepressant Dr.Rahul.pptx
Antidepressants BY Dise.pptx
Antidepressants. CNS stimulants.pdf
Antidepressant pharmacology
Management of anxiety spectrum disorders
Antidepressants. Mood Stabilizers. Psychostimulants

More from Brian Piper (20)

PPTX
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
PPTX
Drug Abuse & Society (RX 462) Presentations-Spring 2014
PPTX
electronic cigarettes
PDF
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
PPTX
Drug abuse and society drug presentations: Spring 2013
PPTX
Sedative & Hypnotic Drugs Part II
PPTX
Sedative & Hypnotic Agents Part I
PPTX
Agents for Bipolar
PPTX
Psychopharmacology of Anxiety Disorders I: GAD & SAD
PPTX
Antipsychotics I
PPTX
Anti Inflammation agents for CNS
PPTX
Anticonvulsants Part II
PPTX
Anticonvulsants Part I
PPTX
ADHD Drugs
PPTX
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
PPTX
Pathophysiology: Migraine & Headache
PPTX
Pathophysiology: Alzheimer's Disease
PPTX
Pathophysiology: Introduction to Neuropsychiatry
PPTX
Pathophysiology: Neuroanatomy Part II
PPTX
Pathophysiology: Neuroanatomy Part I
Current recreational drugs: RX462 Drug Abuse & Society, Spring 2015 Class pre...
Drug Abuse & Society (RX 462) Presentations-Spring 2014
electronic cigarettes
Examination of Sexually Dimorphic Behavior on the Novel-Image Novel-Location ...
Drug abuse and society drug presentations: Spring 2013
Sedative & Hypnotic Drugs Part II
Sedative & Hypnotic Agents Part I
Agents for Bipolar
Psychopharmacology of Anxiety Disorders I: GAD & SAD
Antipsychotics I
Anti Inflammation agents for CNS
Anticonvulsants Part II
Anticonvulsants Part I
ADHD Drugs
Pathophysiology: Myasthenia Gravis & Restless Leg Syndrome
Pathophysiology: Migraine & Headache
Pathophysiology: Alzheimer's Disease
Pathophysiology: Introduction to Neuropsychiatry
Pathophysiology: Neuroanatomy Part II
Pathophysiology: Neuroanatomy Part I

Recently uploaded (20)

PPTX
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
PPTX
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
PDF
شيت_عطا_0000000000000000000000000000.pdf
PDF
TISSUE LECTURE (anatomy and physiology )
PDF
focused on the development and application of glycoHILIC, pepHILIC, and comm...
PPT
Dermatology for member of royalcollege.ppt
PDF
Transcultural that can help you someday.
PPTX
y4d nutrition and diet in pregnancy and postpartum
PPTX
preoerative assessment in anesthesia and critical care medicine
PPTX
Epidemiology of diptheria, pertusis and tetanus with their prevention
PPTX
Neonate anatomy and physiology presentation
PPTX
Acute Coronary Syndrome for Cardiology Conference
PPT
neurology Member of Royal College of Physicians (MRCP).ppt
PDF
Copy of OB - Exam #2 Study Guide. pdf
PDF
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
PPTX
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
DOCX
PEADIATRICS NOTES.docx lecture notes for medical students
PDF
Calcified coronary lesions management tips and tricks
PPTX
09. Diabetes in Pregnancy/ gestational.pptx
PDF
OSCE SERIES ( Questions & Answers ) - Set 5.pdf
HYPERSENSITIVITY REACTIONS - Pathophysiology Notes for Second Year Pharm D St...
Hearthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh
شيت_عطا_0000000000000000000000000000.pdf
TISSUE LECTURE (anatomy and physiology )
focused on the development and application of glycoHILIC, pepHILIC, and comm...
Dermatology for member of royalcollege.ppt
Transcultural that can help you someday.
y4d nutrition and diet in pregnancy and postpartum
preoerative assessment in anesthesia and critical care medicine
Epidemiology of diptheria, pertusis and tetanus with their prevention
Neonate anatomy and physiology presentation
Acute Coronary Syndrome for Cardiology Conference
neurology Member of Royal College of Physicians (MRCP).ppt
Copy of OB - Exam #2 Study Guide. pdf
Comparison of Swim-Up and Microfluidic Sperm Sorting.pdf
Human Reproduction: Anatomy, Physiology & Clinical Insights.pptx
PEADIATRICS NOTES.docx lecture notes for medical students
Calcified coronary lesions management tips and tricks
09. Diabetes in Pregnancy/ gestational.pptx
OSCE SERIES ( Questions & Answers ) - Set 5.pdf

Antidepressants Part II

  • 1. Antidepressants II Brian J. Piper, Ph.D., M.S. January 28, 2013
  • 2. Goals • Light therapy for Seasonal Affective Disorder • Tricyclics & Tetracyclics • Monoamine Oxidase Inhibitors • Serotonin Norepinephrine Reuptake Inhibitors (SNRI) • Saint John’s wort • STAR*D
  • 3. Seasonal Affective Disorder • Depressive symptoms in fall-winter • Light-Therapy (10k lux, 30 min/day) – retina -> hypothalamus (2) -> pineal (3) – morning/ evening – rapid therapeutic onset (days) – good safety profile 2 3 Pail et al. (2011). Neuropsychobiology, 54, 162-164.
  • 4. Light-Therapy Meta-Analysis • Effect Size = (mean Experimental – meanControl)/ Standard Deviation) – 0.20: small – 0.50: medium – 0.80: large <- 0.84 Golden et al. (1995). American Journal of Psychiatry, 162(4), 656-662.
  • 5. Tricyclic Antidepressants (TCA) • Developed from antipsychotic drugs (1960s) • MOA: NET/SERT inhibition; anticholinergic • Gold standard for efficacy • Side effects: sedation • Concern with overdose
  • 6. Affinity (dirty drugs) --------------------------------------------------------------------------- ---------------- -> Eur J Pharmacol. 340 (2–3): 249–258; Psychopharmacology, 114 (4): 559–565.
  • 7. Tetracyclic Antidepressant (TeCA) • Example: mirtazapine (Remeron) • MOA: α2 & 5-HT2 antagonist • Efficacy: equivalent to TCA • Adverse Effects: weight gain, somnolence • Other: onset faster than SSRIs Watanabe et al. (2011). Cochrane Review, Issue 11, CD006528 http://www.howjsay.com/index.php?word=mirtazapine&submit=Submit
  • 8. Serotonin & Norepinephrine Reuptake Inhibitors • Example: venlafaxine (Efexor) • MOA: SERT/NET • Efficacy: good ( > SSRIs) • Adverse Effects: nausea, somnolence, sexual • Half-life: 5 hours
  • 9. SSRI Discontinuation Syndrome • Occurs for ≈2 weeks following withdrawal of antidepressants that block SERT • Symptoms – Flu-like: nausea, dizziness, diarrhea – “brain zaps” – emotional volatility • Solution: prolonged tapering Example Patient (0:52 – 1:13, 4:45 – 6:30): http://www.youtube.com/watch?v=x0HUtRCEMyk Long but sensitive (10 min): http://www.youtube.com/watch?v=2Bt2ftSgDDQ Nielson et al. (2011). Addiction, 107, 900-908.
  • 10. Monoamine Oxidase • MAOA : 5-HT, NE, DA, tyramine • MAOB : phenyltheylamine, DA, tyramine • Inhibition: – Old (1950s): irreversible/non-selective – New (1990s): reversible/selective (MAOA) Stahl, S. (1998). Essential Psychopharmacology, p. 580.
  • 11. Monoamine Oxidase Inhibitors • History: tuberculosis (serendipity) • Example: phenelzine (Nardil) • MOA: blocks breakdown of NE, 5-HT > DA • Efficacy: excellent • Adverse Effects: postural hypotension
  • 12. MAO-I & “cheese” effect • Old view: avoid cheeses, alcohol, etc. • New View: avoid aged cheese, spoiled meats, – Typical American diet does not contain clinically meaningful levels of tyramine (10 mg) Stahl, S. (2008). Essential Psychopharmacology, p. 587-589.
  • 13. MAO-I & “cheese” effect • New View: avoid aged cheese (Cheshire, Danish bleu) McCabe-Sellers et al. (2006). J of Food Composition & Analysis, 19, S58-S65.
  • 14. Serotonin Syndrome • Cluster of autonomic, motor & mental status changes resulting from excess 5-HT (5-HT2A) Agents MAO-Is TCA SSRIs opiate analgesics cough medicines (OTC) antibiotics triptans anti-nausea herbal products abused drugs Boyer & Shannon (2005). New England Journal of Medicine, 352, 1112-1120.
  • 15. Case of Libby Zion • ER visit for fever, agitation, shaking movements 1965 - 1984 • Interns administered meperidine, later restraints • Hyperthermia & cardiac arrest • Intern hours/week = 70
  • 16. Bupropion • MOA: ?, NET & DAT inhibitor • Adverse Effects: dry mouth, high dose seizures • Efficacy: – monotherapy ≈ SRI – augmentation: better than monotherapy • Other: APA recommends as a first-line therapy for moderate depression Moreira, R. (2011). Clinical Drug Investigation, 31(S1), 5-17.
  • 17. Prior Sequenced Treatments Antidepressant Alternatives to Relieve Depression (STAR*D) Trials Multi-site Yes Yes Blinded Yes- Randomized No-Open Controlled Trial Comorbid excluded included Condition Patients Duration 6-12 weeks years
  • 18. STAR*D Design & Results 25.5% 26.6% 25.5% 39.0% 32.9% 29.4% 41.9% Remission: Level 1: 32.9%; Level 2: 30.6%, Level 3: 13.6% Level 2: Switch = 27.0%; Augment = 35%
  • 19. Questions • If you had a family member with MDD, based on the STAR*D results, consider: – How good (efficacious) is the gold standard? – Is there an advantage of augmentation versus switching? – Were any other findings unexpected?
  • 20. MDD: Endocrine Component? Stahl (2008). Essential Psychopharmacology, p. 616-616.
  • 21. SRIs & Pregnancy • Pregnancy is a high-risk period for depression • SRIs may carry slight risks for the fetus – persistent pulmonary hypertension – low birth weight • Untreated MDD does cause fetal risk
  • 22. Summary • Best ----------------------------------Worst Tolerability SRI > SNRI > TCA > MAO-I Efficacy TCA > MAO-I > SNRI > SRI
  • 23. ----------- Stahl (2008). Essential Psychopharmaology, p. 519. -----------------
  • 24. Saint John’s wort (Hypericum perforatum) • MOA: ?, SERT • Adverse Effects: photosensitivity • Concern: quality control • Efficacy: mild to moderate depression
  • 25. MDD Trial ----------------------------------------------------------------------------- Quit 27%-29% Davidson et al. (2002). Journal of the American Medical Association, 287, 1807-1814.
  • 26. Saint John’s wort • MOA: ?, SERT • Adverse Effects: photosensitivity • Other: ↑CYP3A4 • Efficacy: “The available evidence suggests that the hypericum extracts tested in the included trials: a) are superior to placebo in patients with major depression; b) are similarly effective as standard antidepressants; c) and have fewer side effects than standard antidepressants.” Linde et al. (2009). Cochrane Reviews, DOI: 10.1002/14651858.CD000448.pub3
  • 27. Self-Test • The only antidepressant whose mechanism of action includes inhibiting NET & DAT is: – A) hypericum perforatum – B) fluvoxamine – C) mirtazapine – D) bupropion – E) clomipramine

Editor's Notes

  • #2: Libby Zion
  • #4: SAD is not a distinct disorder but is listed as a specifier of MDD or bipolar. DSM IV Criteria: A Regular temporal relationship between the onset of majordepressive episodes and a particular time of the year (unrelated to obvious season-related psychological stressors)B Full remission (or change from depression to mania or hypomania) also occurs at a characteristic time of the year.
  • #5: #’s in ( ) are the reference #.
  • #6: Cardiac effects: hypertension (early and transient), tachycardia, orthostasis and hypotension, and arrhythmias.ECG changes:prolonged QRS, QT, and PR intervals.
  • #8: Mirtazapine was more likely to cause weight gain or increased appetite and somnolence than SSRIs but less likely to cause nausea or vomiting and sexual dysfunction. This agent has no appreciable effects on SERT &amp; NET. Better response compared to SRI SNRI were noted at 2 weeks.This drug is also known as Noradrenergic &amp; Serotonin Specific Antidepressant (NaSSA). Mechanism includes blocking all of the receptors shown.
  • #9: Adverse reactions: Asthenia, sweating, N/V, headache, diarrhea, constipation, anorexia, insomnia, somnolence, dry mouth, dizziness, nervousness, anxiety, abnormal ejaculation/orgasm, impotence in men. Listing of side effects from Wyeth is available here: http://en.wikipedia.org/wiki/VenlafaxineHalf-life of some bioactive metabolites is 10 hours.
  • #10: Symptoms described as &quot;brain zaps&quot;, &quot;brain shocks&quot;, &quot;brain shivers&quot;, &quot;brain pulse-waves&quot;, &quot;head shocks&quot;, or &quot;cranial zings“.  Very gradual discontinuation of dosing may be beneficial.
  • #11: Newer agents include moclobemide (not yet approved in US).
  • #12: Isoniazid (I so niazid): http://www.howjsay.com/index.php?word=isoniazid&amp;submit=Submit
  • #13: 400 mg of tyramine may be needed to increase blood pressure in normal individuals but may be as low as 10 mg in individuals taking an irreversible/nonselective MAO-I (phenelzine).
  • #14: Some international foods may be problematic (Marmite yeast extract, shrimp)
  • #15: 5-HT2A antagonists can prevent the effects of serotonin toxicity.
  • #16: The intern was responsible for 40 patients at the same time! Meperidine has weak SRI effects.
  • #17: Bupropion is a weak inhibitor of NET &amp; DAT but metabolites are biologically active (weakly too). This may be good as too much DAT binding could lead to abuse. Dry mouth noted in 15% versus 7% receiving placebo. Half-life is 10 hours but longer for active metabolites.
  • #18: Many depressed patients have other psychiatric and medical conditions.
  • #19: Venlafaxine: Serotonin/Norepinephrine Reuptake Inhibitor; Sertraline/Citalopram: Serotonin Reuptake Inhibitors; Buspirone: 5-HT1A agonist.
  • #22: 14% of pregnant women experience depression.
  • #23: ECT would rank above TCA for efficacy.
  • #26: Sertraline dose started at 50 mg/day and could be increased, as needed to 150 mg/day. The highest dose used clinically is 300.
  • #27: The association of country of origin and precision with effects sizes complicates the interpretation.